Regulatory Reference
NDA vs ANDA — FDA Pathway Comparison
Compare New Drug Applications (505(b)(1)) and Abbreviated New Drug Applications (505(j)) — evidence requirements, review clocks, exclusivity, and when each pathway applies.
At a glance
| Feature | NDA (505(b)(1)) | ANDA (505(j)) |
|---|---|---|
| Product | New brand-name small molecule | Generic copy of Reference Listed Drug (RLD) |
| Clinical evidence | Full safety & efficacy package | Bioequivalence (PK) — no new efficacy trials |
| Legal basis | 21 CFR 314 — FDCA 505(b)(1) | 21 CFR 314 Subpart C — 505(j) |
| Typical development | 8–12 years IND → Phase III → NDA | 1–3 years BE + CMC vs RLD |
| PDUFA review goal | 10–12 months standard; 6 months priority | 10 months standard ANDA goal |
| Exclusivity granted | 5 yr NCE / 3 yr new clinical investigation | 180 days (first successful Para IV filer) |
| Orange Book | Listed as RLD when approved | Generic must match RLD dosage form, route, strength |
NDA — when you need a full application
An NDA is required for a new molecular entity or a drug that cannot rely on an existing approved product's safety and efficacy record. The sponsor submits Modules 2–5 (summaries, quality, nonclinical, clinical) demonstrating the product is safe and effective for the proposed labeling.
FDA has 60 days to file or refuse-to-file (RTF) the application. Substantive review follows PDUFA goals. Outcomes: approval, Complete Response Letter (CRL), or withdrawal.
ANDA — generics and bioequivalence
An ANDA demonstrates that the generic product is the same as the RLD in dosage form, route, strength, and conditions of use, and is bioequivalent — not clinically superior or different.
Bioequivalence standard: 90% confidence intervals for Cmax and AUC must fall within 80–125% of the reference product in a typical crossover PK study (fasting and/or fed, per product-specific guidance).
Patent certifications: ANDA applicants certify against Orange Book patents — Paragraph IV (invalid/not infringed) triggers 30-month stay and potential 180-day exclusivity for the first successful challenger.
NDA vs ANDA vs BLA
| Feature | NDA | ANDA | BLA |
|---|---|---|---|
| Product type | New small molecule | Generic small molecule | Biological product |
| Clinical data | Full safety & efficacy | BE studies only | Full safety & efficacy |
| Manufacturing emphasis | CMC in Module 3 | Sameness to RLD + CMC | Process is the product |
| Typical review | 6–12 months PDUFA | 10–30 months (litigation variable) | 6–12 months PDUFA |